{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:30:41Z","timestamp":1793323841802,"version":"4.5.0"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009529","name":"COMSATS University Islamabad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009529","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jconrel.2020.11.021","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T04:17:34Z","timestamp":1605241054000},"page":"1152-1167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":230,"special_numbering":"C","title":["Neurodegenerative diseases and effective drug delivery: A review of challenges and novel therapeutics"],"prefix":"10.1016","volume":"330","author":[{"given":"Amna","family":"Akhtar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisa","family":"Andleeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayyba Sher","family":"Waris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoomeh","family":"Bazzar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali-Reza","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasir Raza","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Yar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2020.11.021_bb0005","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00401-018-1812-4","article-title":"The role of brain barriers in fluid movement in the CNS: is there a \u2018glymphatic\u2019 system?","volume":"135","author":"Abbott","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0010","first-page":"252","article-title":"Drug delivery to the central nervous system: a review","volume":"6","author":"Misra","year":"2003","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0015","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood\u2013brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/cbdd.12268","article-title":"Novel central nervous system drug delivery systems","volume":"83","author":"Stockwell","year":"2014","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0025","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1039\/C6CS00076B","article-title":"Blood\u2013brain barrier shuttle peptides: an emerging paradigm for brain delivery","volume":"45","author":"Oller-Salvia","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0030","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.7150\/thno.21254","article-title":"Current strategies for brain drug delivery","volume":"8","author":"Dong","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0035","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1039\/C5BM00383K","article-title":"Strategies for transporting nanoparticles across the blood\u2013brain barrier","volume":"4","author":"Zhang","year":"2016","journal-title":"Biomaterials Science"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0040","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.2147\/IJN.S117210","article-title":"Getting into the brain: liposome-based strategies for effective drug delivery across the blood\u2013brain barrier","volume":"11","author":"Vieira","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0045","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s11095-013-1156-7","article-title":"Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases","volume":"30","author":"Pehlivan","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood\u2013brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0055","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1517\/17425247.5.2.155","article-title":"Polymeric nanoparticles for the drug delivery to the central nervous system","volume":"5","author":"Tosi","year":"2008","journal-title":"Expert Opinion Drug Delivery"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0060","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pharmthera.2004.08.001","article-title":"Delivery of therapeutic agents to the central nervous system: the problems and the possibilities","volume":"104","author":"Begley","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0065","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.08.008","article-title":"Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?","volume":"71","author":"Kreuter","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0070","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.surneu.2004.06.008","article-title":"Nanotechnology approaches for the regeneration and neuroprotection of the central nervous system","volume":"63","author":"Silva","year":"2005","journal-title":"Surg. Neurol."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0075","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.biopha.2018.12.133","article-title":"Applications of nanotechnology in drug delivery to the central nervous system","volume":"111","author":"Saeedi","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0080","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/pharmaceutics10040269","article-title":"Blood-brain delivery methods using nanotechnology","volume":"10","author":"Teleanu","year":"2018","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.jconrel.2020.11.021_bb0085","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.drudis.2018.05.018","article-title":"Nanogels as potential drug nanocarriers for CNS drug delivery","volume":"23","author":"Vashist","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0090","first-page":"1","article-title":"Theranostical application of nanomedicine for treating central nervous system disorders","author":"Ran","year":"2018","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2003.12.016","article-title":"The blood\u2013brain barrier: an overview: structure, regulation, and clinical implications","volume":"16","author":"Ballabh","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0100","doi-asserted-by":"crossref","first-page":"a020412","DOI":"10.1101\/cshperspect.a020412","article-title":"The blood-brain barrier","volume":"7","author":"Daneman","year":"2015","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.drudis.2006.10.013","article-title":"Blood\u2013brain barrier delivery","volume":"12","author":"Pardridge","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0110","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2008.01.003","article-title":"The blood-brain barrier in health and chronic neurodegenerative disorders","volume":"57","author":"Zlokovic","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0115","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.2174\/1381612822666160726112115","article-title":"Potential pathways for CNS drug delivery across the blood-cerebrospinal fluid barrier","volume":"22","author":"Strazielle","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10014-016-0255-7","article-title":"Blood\u2013brain barrier and blood\u2013cerebrospinal fluid barrier in normal and pathological conditions","volume":"33","author":"Ueno","year":"2016","journal-title":"Brain Tumor Pathology"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0125","doi-asserted-by":"crossref","unstructured":"Engelhardt B, Sorokin L. The blood\u2013brain and the blood\u2013cerebrospinal fluid barriers: function and dysfunction. Seminars Immunopathology: Springer; 2009. p. 497\u2013511.","DOI":"10.1007\/s00281-009-0177-0"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12987-020-00196-2","article-title":"Choroid plexus and the blood\u2013cerebrospinal fluid barrier in disease","volume":"17","author":"Sol\u00e1r","year":"2020","journal-title":"Fluids and Barriers of the CNS"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-030-19515-1_1","article-title":"Overview of Mechanisms Underlying Neuroimmune Diseases","author":"Sonar","year":"2019","journal-title":"Neuroimmune Diseases: Springer"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0140","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00401-018-1807-1","article-title":"Molecular anatomy and functions of the choroidal blood-cerebrospinal fluid barrier in health and disease","volume":"135","author":"Ghersi-Egea","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0145","doi-asserted-by":"crossref","unstructured":"Rosenberg G. Cerebrospinal fluid: Formation, absorption, markers, and relationship to blood\u2013brain barrier. Primer on Cerebrovascular Diseases (Second Edition): Elsevier; 2017. p. 25\u201331.","DOI":"10.1016\/B978-0-12-803058-5.00004-7"},{"issue":"111","key":"10.1016\/j.jconrel.2020.11.021_bb0150","first-page":"1","article-title":"A choroid plexus epithelial cell-based model of the human blood-cerebrospinal fluid barrier to study bacterial infection from the basolateral side","author":"Dinner","year":"2016","journal-title":"Journal of visualized experiments: JoVE"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","article-title":"Overcoming the blood\u2013brain tumor barrier for effective glioblastoma treatment","volume":"19","author":"Van Tellingen","year":"2015","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0160","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/B978-0-12-813689-8.00017-3","article-title":"Recent advances in understanding of blood\u2013brain tumor barrier (BTB) permeability mechanisms that enable better detection and treatment of brain tumors","author":"Khaitan","year":"2018","journal-title":"Drug Targeting and Stimuli Sensitive Drug Delivery Systems: Elsevier"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0165","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.3390\/ijms20123108","article-title":"Approaches to CNS drug delivery with a focus on transporter-mediated transcytosis","volume":"20","author":"Abdul Razzak","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0170","first-page":"60","article-title":"Polymeric nanoparticles drug delivery to brain: a review","volume":"2","author":"Sharma","year":"2015","journal-title":"Int. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0175","article-title":"The blood-brain barrier: physiology and strategies for drug delivery","author":"Pandit","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0180","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2147\/IJN.S61288","article-title":"Current approaches to enhance CNS delivery of drugs across the brain barriers","volume":"9","author":"Lu","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0185","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/cbdd.12268","article-title":"Novel central nervous system drug delivery systems","volume":"83","author":"Stockwell","year":"2014","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0190","first-page":"60","article-title":"Polymeric nanoparticles drug delivery to brain: a review","volume":"2","author":"Sharma","year":"2015","journal-title":"Int. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0195","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.brainresbull.2019.11.017","article-title":"Approaches for encephalic drug delivery using nanomaterials: the current status","volume":"155","author":"Anoop","year":"2020","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0200","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40263-016-0405-9","article-title":"Crossing the blood\u2013brain barrier: recent advances in drug delivery to the brain","volume":"31","author":"Patel","year":"2017","journal-title":"Cns Drugs"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0205","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2147\/DDDT.S100075","article-title":"Drug delivery in overcoming the blood\u2013brain barrier: role of nasal mucosal grafting","volume":"11","author":"Marianecci","year":"2017","journal-title":"Drug Design, Development Therapy"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0210","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/187221109787158355","article-title":"CNS drug delivery systems: novel approaches","volume":"3","author":"Pathan","year":"2009","journal-title":"Recent Patents on Drug Delivery & Formulation"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0215","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/scipharm87010006","article-title":"Overcoming the blood\u2013brain barrier. challenges and tricks for CNS drug delivery","volume":"87","author":"Bors","year":"2019","journal-title":"Scientia Pharmaceutica"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0220","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-010-0466-4","article-title":"Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: implications for chemotherapy","volume":"104","author":"Joshi","year":"2011","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0225","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrd.2015.21","article-title":"From blood\u2013brain barrier to blood\u2013brain interface: new opportunities for CNS drug delivery","volume":"15","author":"Banks","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0230","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejps.2010.05.003","article-title":"Strategy for effective brain drug delivery","volume":"40","author":"Alam","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0235","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1021\/cn300191b","article-title":"Noninvasive and targeted drug delivery to the brain using focused ultrasound","volume":"4","author":"Burgess","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0240","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/016173460803000304","article-title":"Noninvasive and transient blood-brain barrier opening in the hippocampus of Alzheimer\u2019s double transgenic mice using focused ultrasound","volume":"30","author":"Choi","year":"2008","journal-title":"Ultrason. Imaging"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0245","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.beem.2014.12.001","article-title":"Neuronopathic lysosomal storage disorders: approaches to treat the central nervous system","volume":"29","author":"Scarpa","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0250","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13052-018-0563-0","article-title":"Possible strategies to cross the blood\u2013brain barrier","volume":"44","author":"Bellettato","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0255","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1124\/mi.3.2.90","article-title":"Blood-brain barrier drug targeting: the future of brain drug development","volume":"3","author":"Pardridge","year":"2003","journal-title":"Mol. Interv."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0260","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2174\/156802609787521571","article-title":"Recent advances in medicinal chemistry and pharmaceutical technology-strategies for drug delivery to the brain","volume":"9","author":"Denora","year":"2009","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0265","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1471-2202-9-S3-S5","article-title":"Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease","volume":"9","author":"Hanson","year":"2008","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0270","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0275","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","article-title":"Evaluation of intranasal delivery route of drug administration for brain targeting","volume":"143","author":"Erd\u0151","year":"2018","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0280","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jconrel.2005.07.024","article-title":"Targeted nanoparticles for drug delivery through the blood\u2013brain barrier for Alzheimer\u2019s disease","volume":"108","author":"Roney","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0285","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: overcoming blood\u2013brain barrier to treat neurodegenerative diseases","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0290","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/320941","article-title":"Blood brain barrier: a challenge for effectual therapy of brain tumors","volume":"2015","author":"Bhowmik","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0295","series-title":"Applications of Cell Immobilisation Biotechnology","first-page":"211","article-title":"Cell encapsulation therapy for malignant gliomas","author":"Rokstad","year":"2005"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0300","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/neuonc\/3.3.201","article-title":"Cell encapsulation technology as a therapeutic strategy for CNS malignancies","volume":"3","author":"Visted","year":"2001","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0305","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.addr.2014.01.010","article-title":"Drug and cell encapsulation: alternative delivery options for the treatment of malignant brain tumors","volume":"67","author":"Bhujbal","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0310","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJM200105173442006","article-title":"Neurodegenerative diseases and prions","volume":"344","author":"Prusiner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0315","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","article-title":"Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology","volume":"79","author":"Armstrong","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0320","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/ph11020044","article-title":"Old drugs as new treatments for neurodegenerative diseases","volume":"11","author":"Dur\u00e3es","year":"2018","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0325","first-page":"3","article-title":"New hopes and challenges for treatment of neurodegenerative disorders: great opportunities for young neuroscientists","volume":"4","author":"Kiaei","year":"2013","journal-title":"Basic and Clinical Neuroscience"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0330","doi-asserted-by":"crossref","first-page":"319","DOI":"10.15171\/apb.2016.044","article-title":"Nanomedicine in central nervous system (CNS) disorders: a present and future prospective","volume":"6","author":"Soni","year":"2016","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0335","doi-asserted-by":"crossref","first-page":"S232","DOI":"10.1038\/sj.bjp.0706400","article-title":"The role of inflammation in CNS injury and disease","volume":"147","author":"Lucas","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0340","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2567.2009.03225.x","article-title":"Inflammation in neurodegenerative diseases","volume":"129","author":"Amor","year":"2010","journal-title":"Immunology"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/DDC-120001481","article-title":"Nanoparticle technology for drug delivery across the blood-brain barrier","volume":"28","author":"Lockman","year":"2002","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0350","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/238428","article-title":"Nanoparticles for brain drug delivery","volume":"2013","author":"Masserini","year":"2013","journal-title":"ISRN Biochemistry"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0355","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.addr.2011.12.006","article-title":"Polymeric nanoparticles for drug delivery to the central nervous system","volume":"64","author":"Patel","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0360","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s11427-017-9292-7","article-title":"Theranostical application of nanomedicine for treating central nervous system disorders","volume":"61","author":"Ran","year":"2018","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0365","first-page":"73","article-title":"Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging","author":"Sahoo","year":"2017","journal-title":"Nanomedicine in Cancer: Pan Stanford"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0370","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.addr.2011.12.006","article-title":"Polymeric nanoparticles for drug delivery to the central nervous system","volume":"64","author":"Patel","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0375","doi-asserted-by":"crossref","first-page":"679","DOI":"10.4103\/1673-5374.156943","article-title":"Restoring nervous system structure and function using tissue engineered living scaffolds","volume":"10","author":"Struzyna","year":"2015","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0380","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1002\/adma.201500762","article-title":"An injectable, self-healing hydrogel to repair the central nervous system","volume":"27","author":"Tseng","year":"2015","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0385","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/rb\/rbu017","article-title":"Strategies for regeneration of components of nervous system: scaffolds, cells and biomolecules","volume":"2","author":"Tian","year":"2015","journal-title":"Regenerative Biomaterials"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0390","doi-asserted-by":"crossref","first-page":"100788","DOI":"10.1016\/j.isci.2019.100788","article-title":"Biomimetic materials and their utility in modeling the 3-dimensional neural environment","volume":"23","author":"Cembran","year":"2020","journal-title":"Iscience"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0395","article-title":"Three dimensional collagen scaffold promotes intrinsic vascularisation for tissue engineering applications","volume":"11","author":"Chan","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0400","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40001-017-0279-4","article-title":"Clinical and biometrical 12-month follow-up in patients after reconstruction of the sural nerve biopsy defect by the collagen-based nerve guide Neuromaix","volume":"22","author":"Bozkurt","year":"2017","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0405","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1098\/rsfs.2012.0016","article-title":"Hyaluronic acid-based scaffold for central neural tissue engineering","volume":"2","author":"Wang","year":"2012","journal-title":"Interface Focus"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0410","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/j.actbio.2009.03.033","article-title":"Development of hyaluronic acid-based scaffolds for brain tissue engineering","volume":"5","author":"Wang","year":"2009","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0415","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1002\/jnr.21358","article-title":"Enhanced neuronal differentiation in a three-dimensional collagen-hyaluronan matrix","volume":"85","author":"Br\u00e4nnvall","year":"2007","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0420","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.eurpolymj.2012.12.009","article-title":"Chitosan-based biomaterials for tissue engineering","volume":"49","author":"Croisier","year":"2013","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0425","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jmbbm.2012.09.012","article-title":"Chitosan fibers with improved biological and mechanical properties for tissue engineering applications","volume":"20","author":"Albanna","year":"2013","journal-title":"J. Mech. Behav. Biomed. Mater."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0430","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/adhm.201600095","article-title":"Functional 3D neural mini-tissues from printed gel-based bioink and human neural stem cells","volume":"5","author":"Gu","year":"2016","journal-title":"Advanced Healthcare Materials"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0435","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bioactmat.2016.11.001","article-title":"Bioactive polymeric scaffolds for tissue engineering","volume":"1","author":"Stratton","year":"2016","journal-title":"Bioactive materials"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0440","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.msec.2017.03.264","article-title":"Biomaterials and cells for neural tissue engineering: current choices","volume":"77","author":"Sensharma","year":"2017","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0445","doi-asserted-by":"crossref","first-page":"86","DOI":"10.5222\/ankem.2012.086","article-title":"Poly (lactic-co-glycolic acid) based drug delivery devices for tissue engineering and regenerative medicine","volume":"26","author":"Kerimoglu","year":"2012","journal-title":"Ankem Derg"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0450","doi-asserted-by":"crossref","first-page":"8749","DOI":"10.2147\/IJN.S144545","article-title":"Development of surface-engineered PLGA nanoparticulate-delivery system of Tet1-conjugated nattokinase enzyme for inhibition of A\u03b240 plaques in Alzheimer\u2019s disease","volume":"12","author":"Bhatt","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0455","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jconrel.2016.11.025","article-title":"Nanotechnology-based drug delivery systems for Alzheimer\u2019s disease management: technical, industrial, and clinical challenges","volume":"245","author":"Wen","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0460","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.addr.2019.02.007","article-title":"Nanoparticle technology and stem cell therapy team up against neurodegenerative disorders","volume":"148","author":"Vissers","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0465","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/npp.2013.237","article-title":"Regenerative therapies for central nervous system diseases: a biomaterials approach","volume":"39","author":"Tam","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0470","article-title":"de Jesus PdCC, bi H, Tedesco AC. Polymer scaffolds as drug delivery systems","volume":"109621","author":"Calori","year":"2020","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0475","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/npp.2013.237","article-title":"Regenerative therapies for central nervous system diseases: a biomaterials approach","volume":"39","author":"Tam","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0480","article-title":"Biomaterial scaffolds in regenerative therapy of the central nervous system","volume":"2018","author":"Wang","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0485","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/jbm.a.34454","article-title":"Characterization of hyaluronan\u2013methylcellulose hydrogels for cell delivery to the injured spinal cord","volume":"101","author":"Caicco","year":"2013","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0490","first-page":"326","article-title":"Rediscovering an old friend, IGF-I: potential use in the treatment of neurodegenerative diseases","volume":"20","author":"Dor\u00e9","year":"1997","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0495","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/00001813-200310000-00001","article-title":"Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment","volume":"14","author":"Bohula","year":"2003","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0500","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0166-2236(95)93892-2","article-title":"The developing CNS: a scenario for the action of proinsulin, insulin and insulin-like growth factors","volume":"18","author":"de Pablo","year":"1995","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0505","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0510","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0515","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1517\/17460441.2013.805199","article-title":"Neural stem cells as tools for drug discovery: novel platforms and approaches","volume":"8","author":"Gorba","year":"2013","journal-title":"Expert Opin. Drug Discovery"},{"issue":"4","key":"10.1016\/j.jconrel.2020.11.021_bb0520","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.drudis.2019.01.007","article-title":"Induced pluripotent stem cells for neural drug discovery","volume":"24","author":"Farkhondeh","year":"2019","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0525","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrd3577","article-title":"Induced pluripotent stem cells\u2014opportunities for disease modelling and drug discovery","volume":"10","author":"Grskovic","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0530","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrd.2016.245","article-title":"Induced pluripotent stem cell technology: a decade of progress","volume":"16","author":"Shi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0535","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainresbull.2015.12.003","article-title":"Toward more predictive genetic mouse models of Alzheimer\u2019s disease","volume":"122","author":"Onos","year":"2016","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0540","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/nyas.13052","article-title":"Disease models for the development of therapies for lysosomal storage diseases","volume":"1371","author":"Xu","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0545","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s00335-017-9687-6","article-title":"Bridging the gap: large animal models in neurodegenerative research","volume":"28","author":"Eaton","year":"2017","journal-title":"Mamm. Genome"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0550","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.stem.2012.04.027","article-title":"Induced pluripotent stem cells from patients with Huntington\u2019s disease show CAG-repeat-expansion-associated phenotypes","volume":"11","author":"Hi","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0555","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.stem.2013.01.009","article-title":"Modeling Alzheimer\u2019s disease with iPSCs reveals stress phenotypes associated with intracellular A\u03b2 and differential drug responsiveness","volume":"12","author":"Kondo","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jconrel.2020.11.021_bb0560","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/768391","article-title":"A comparative view on human somatic cell sources for iPSC generation","volume":"2014","author":"Raab","year":"2014","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.jconrel.2020.11.021_bb0565","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/mp.2017.40","article-title":"Pluripotent stem cells in neuropsychiatric disorders","volume":"22","author":"Soliman","year":"2017","journal-title":"Mol. Psychiatry"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920306702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920306702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:04:09Z","timestamp":1759161849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920306702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":113,"alternative-id":["S0168365920306702"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.11.021","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurodegenerative diseases and effective drug delivery: A review of challenges and novel therapeutics","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}